Neuraminidase inhibition improves endothelial function in diabetic mice
Christopher Foote, Francisco I. Ramirez‐Perez, James Smith, Thaysa Ghiarone, Mariana Morales‐Quinones, Neil J. McMillan, Marc A. Augenreich, Gavin Power, Katherine Burr, Annayya R. Aroor, Shawn B. Bender, Camila Manrique‐Acevedo, Jaume Padilla, Luis A. Martinez‐Lemus
Abstract
This work identifies neuraminidase as a key mediator of endothelial dysfunction in type 2 diabetes that may serve as a biomarker for impaired endothelial function and predictive of development and progression of cardiovascular pathologies associated with type 2 diabetes (T2D). Data show that intervention with the neuraminidase inhibitor zanamivir at effective plasma concentrations may represent a novel pharmacological strategy for restoring the glycocalyx and ameliorating endothelial dysfunction.